CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 19 enrolled
Drug / intervention
Adverse Drug Reaction ADRe Profile for Polypharmacyother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03955133
NCT03955133N/ACompleted

Polypharmacy and Adverse Drug Reactions: Nurse-led Intervention to Minimise Adverse Drug Reactions for Older Adults in Care Homes: a Quality Improvement Process Intervention

Swansea University·interventional·Posted May 17, 2019·Updated Aug 17, 2021

In Brief

A clinical study evaluating Adverse Drug Reaction ADRe Profile for Polypharmacy for Polypharmacy. Completed, enrolled 19 participants across 1 site.

Detailed Summary

Polypharmacy, the use of multiple or inappropriate medications, has the potential to harm older adults by causing cognitive impairment, falls, and hospitalisations. The nurse-led intervention (The ADRe Profile) to review mental health medicines has demonstrated improved care quality by: identifying serious adverse drug reactions (ADRs); reducing prescription of mental health medicines; reducing the prevalence of pain and nausea; and, increasing non-urgent national health service (NHS) contacts. The investigators will develop ADRe to encompass medicines commonly prescribed in primary care and evaluate intervention implementation in care homes in Aneurin Bevan University Health Board.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPolypharmacy
CountriesUnited Kingdom

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedMay 17, 2019
Enrollment StartDec 18, 2018
Primary CompletionMay 31, 2019
Study CompletionDec 31, 2020
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 7.1 years ago

Interventions

Adverse Drug Reaction ADRe Profile for Polypharmacyother

PADRe asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the British National Formulary (BNF) and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts. A full description is published (references below).